Nikesh N Shah

Dr. Nikesh N Shah

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
EBElizabeth Budde
Elizabeth Budde
HZHuilai Zhang
Huilai Zhang
WKWon Seog Kim
Won Seog Kim
DMDai Maruyama
Dai Maruyama
EREduardo Rego
Eduardo Rego
JWJason Westin
Jason Westin
PURPOSE: Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS: In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS: A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx. CONCLUSION: Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

1 June 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
NSNikesh N Shah
Nikesh N Shah
YXYizhao Xi
Yizhao Xi
YLYuan Liu
Yuan Liu
JKJean L. Koff
Jean L. Koff
CFChristopher R. Flowers
Christopher R. Flowers
Jonathon B. CohenJonathon B. Cohen
Jonathon B. Cohen

30 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JCJahnavi V Chaudhari
Jahnavi V Chaudhari
NSNikesh N Shah
Nikesh N Shah
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL)

1 January 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
RMRichard L. Martin
Richard L. Martin
MGMichael J. Grant
Michael J. Grant
SKStephen Kimani
Stephen Kimani
SMShonali Midha
Shonali Midha
JMJori May
Jori May
JGJennifer R. Green
Jennifer R. Green
PURPOSE: COVID-19 challenged medical practice and graduate medical education. Building on previous initiatives, we describe and reflect on the formative process and goals of the Hematology-Oncology Collaborative Videoconferencing Learning Initiative, a trainee-led multi-institutional virtual COVID-19 learning model.METHODS: Clinical fellows and faculty from 13 US training institutions developed consensus needs, goals, and objectives, recruited presenters, and generated a multidisciplinary COVID-19 curriculum. Weekly Zoom conferences consisted of two trainee-led instructional segments and a trainee-moderated faculty Q&A panel. Hematology-oncology training program faculty and trainees were the targeted audience. Leadership evaluations consisted of anonymized baseline and concluding mixed methods surveys. Presenter evaluations consisted of session debriefs and two structured focus groups. Conference evaluations consisted of attendance, demographics, and pre- or postmultiple-choice questions on topic learning objectives.RESULTS: In 6 weeks, the initiative produced five conferences: antivirals, anticoagulation, pulmonology, provider resilience, and resource scarcity ethics. The average attendance was 100 (range 57-185). Among attendees providing both pre- and postconference data, group-level knowledge appeared to increase: antiviral (n = 46) pre-/postcorrect 82.6%/97.8% and incorrect 10.9%/2.2%, anticoagulation (n = 60) pre-/postcorrect 75%/93.3% and incorrect 15%/6.7%, and pulmonary (n = 21) pre-/postcorrect 66.7%/95.2% and incorrect 33.3%/4.8%. Although pulmonary management comfort appeared to increase, comfort managing of antivirals and anticoagulation was unchanged. At the conclusion of the pilot, leadership trainees reported improved self-confidence organizing multi-institutional collaborations, median (interquartile range) 58.5 (50-64) compared with baseline 34 (26-39), but did not report improved confidence in other educational or leadership skills.CONCLUSION: During crisis, trainees built a multi-institutional virtual education platform for the purposes of sharing pandemic experiences and knowledge. Accomplishment of initiative goals was mixed. Lessons learned from the process and goals may improve future disaster educational initiatives.

27 October 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
NSNikesh N Shah
Nikesh N Shah
FCFranco Castillo-Tokumori
Franco Castillo-Tokumori
JWJunmin Whiting
Junmin Whiting
DBDavid Boulware
David Boulware
JSJose Sandoval-Sus
Jose Sandoval-Sus
BSBijal D. Shah
Bijal D. Shah
Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma with no current standard of care. Treatment options range from surveillance to intensive chemoimmunotherapy followed by autologous stem ce...

13 April 2020 in Advances in Cell and Gene Therapy
Verified
Journal Article
Closed access
PDF file
NSNikesh N Shah
Nikesh N Shah
RKRami S. Komrokji
Rami S. Komrokji